Abdulrahim Saleh Alrasheed, Tala Abdullah Aljahdali, Israa Aqeel Alghafli, Ghadeer Aqeel Alghafli, Majd Fouad Almuslim, Noor Mohammad AlMohish, Majed Mohammad Alabdali
{"title":"干细胞治疗缺血性卒中的安全性和有效性:一项全面的系统评价和荟萃分析。","authors":"Abdulrahim Saleh Alrasheed, Tala Abdullah Aljahdali, Israa Aqeel Alghafli, Ghadeer Aqeel Alghafli, Majd Fouad Almuslim, Noor Mohammad AlMohish, Majed Mohammad Alabdali","doi":"10.3390/jcm14062118","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Although recent advancements in ischemic stroke management have reduced associated mortality rates, there remains a pressing need for more reliable, efficacious, and well-tolerated therapeutic approaches due to the narrow therapeutic window of current treatment approaches. The current meta-analysis sought to evaluate the safety and efficacy of stem cell-based therapeutic options for patients with ischemic stroke. <b>Methods:</b> PubMed, Web of Science, and Cochrane library databases were searched to retrieve randomized controlled trials (RCTs) evaluating the efficacy and safety of stem cell therapy (SCT) in ischemic stroke patients. Key outcomes included the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA), infarct size, and safety profile. The random effects model with the continuous method was used to calculate the pooled effect size in Review Manager 5.4.1, and subgroup analyses were performed based on demographics, stroke duration, and SCT delivery protocols. <b>Results:</b> A total of 18 RCTs involving 1026 patients were analyzed, with 538 in the treatment group and 488 in the control group. The mean change in NIHSS score was comparable between groups [MD = -0.80; 95% CI: -2.25, 0.65, <i>p</i> < 0.0001]. However, SCT showed better outcomes in mRS [MD = -0.56; 95% CI: -0.76, -0.35, <i>p</i> = 0.30] and BI scores [MD = 12.00; 95% CI: 4.00, 20.00, <i>p</i> = 0.007]. Additionally, the mean change in FMA score was significantly greater with SCT [MD = 18.16; 95% CI: 6.58, 29.75, <i>p</i> = 0.03]. The mean change in infarct volume also favored stem cell therapy [MD = 8.89; 95% CI: -5.34, 23.12, <i>p</i> = 0.08]. The safety profile was favorable, with adverse event rates comparable to or lower than controls. <b>Conclusions:</b> SCT offers a safe and effective approach to improving functional outcomes in stroke patients, particularly with early intervention. These findings highlight the potential of SCT in ischemic stroke rehabilitation while underscoring the need for standardized protocols and long-term safety evaluation.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"14 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943215/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety and Efficacy of Stem Cell Therapy in Ischemic Stroke: A Comprehensive Systematic Review and Meta-Analysis.\",\"authors\":\"Abdulrahim Saleh Alrasheed, Tala Abdullah Aljahdali, Israa Aqeel Alghafli, Ghadeer Aqeel Alghafli, Majd Fouad Almuslim, Noor Mohammad AlMohish, Majed Mohammad Alabdali\",\"doi\":\"10.3390/jcm14062118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Although recent advancements in ischemic stroke management have reduced associated mortality rates, there remains a pressing need for more reliable, efficacious, and well-tolerated therapeutic approaches due to the narrow therapeutic window of current treatment approaches. The current meta-analysis sought to evaluate the safety and efficacy of stem cell-based therapeutic options for patients with ischemic stroke. <b>Methods:</b> PubMed, Web of Science, and Cochrane library databases were searched to retrieve randomized controlled trials (RCTs) evaluating the efficacy and safety of stem cell therapy (SCT) in ischemic stroke patients. Key outcomes included the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA), infarct size, and safety profile. The random effects model with the continuous method was used to calculate the pooled effect size in Review Manager 5.4.1, and subgroup analyses were performed based on demographics, stroke duration, and SCT delivery protocols. <b>Results:</b> A total of 18 RCTs involving 1026 patients were analyzed, with 538 in the treatment group and 488 in the control group. The mean change in NIHSS score was comparable between groups [MD = -0.80; 95% CI: -2.25, 0.65, <i>p</i> < 0.0001]. However, SCT showed better outcomes in mRS [MD = -0.56; 95% CI: -0.76, -0.35, <i>p</i> = 0.30] and BI scores [MD = 12.00; 95% CI: 4.00, 20.00, <i>p</i> = 0.007]. Additionally, the mean change in FMA score was significantly greater with SCT [MD = 18.16; 95% CI: 6.58, 29.75, <i>p</i> = 0.03]. The mean change in infarct volume also favored stem cell therapy [MD = 8.89; 95% CI: -5.34, 23.12, <i>p</i> = 0.08]. The safety profile was favorable, with adverse event rates comparable to or lower than controls. <b>Conclusions:</b> SCT offers a safe and effective approach to improving functional outcomes in stroke patients, particularly with early intervention. These findings highlight the potential of SCT in ischemic stroke rehabilitation while underscoring the need for standardized protocols and long-term safety evaluation.</p>\",\"PeriodicalId\":15533,\"journal\":{\"name\":\"Journal of Clinical Medicine\",\"volume\":\"14 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943215/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcm14062118\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm14062118","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:尽管缺血性脑卒中管理的最新进展降低了相关的死亡率,但由于当前治疗方法的治疗窗口狭窄,仍然迫切需要更可靠、有效和耐受性良好的治疗方法。当前的荟萃分析旨在评估基于干细胞的治疗方案对缺血性卒中患者的安全性和有效性。方法:检索PubMed、Web of Science和Cochrane图书馆数据库,检索评估干细胞治疗(SCT)对缺血性脑卒中患者疗效和安全性的随机对照试验(rct)。主要结局包括美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)、Barthel指数(BI)、Fugl-Meyer评估(FMA)、梗死面积和安全性。采用Review Manager 5.4.1中的随机效应模型和连续方法计算合并效应大小,并根据人口统计学、卒中持续时间和SCT给药方案进行亚组分析。结果:共纳入18项rct,共纳入1026例患者,其中治疗组538例,对照组488例。各组间NIHSS评分的平均变化具有可比性[MD = -0.80;95% CI: -2.25, 0.65, p < 0.0001]。然而,SCT在mRS中表现出更好的结果[MD = -0.56;95% CI: -0.76, -0.35, p = 0.30]和BI评分[MD = 12.00;95% CI: 4.00, 20.00, p = 0.007]。此外,SCT组FMA评分的平均变化更大[MD = 18.16;95% CI: 6.58, 29.75, p = 0.03]。梗死体积的平均变化也有利于干细胞治疗[MD = 8.89;95% CI: -5.34, 23.12, p = 0.08]。安全性良好,不良事件发生率与对照组相当或低于对照组。结论:SCT提供了一种安全有效的方法来改善脑卒中患者的功能结局,特别是早期干预。这些发现强调了SCT在缺血性卒中康复中的潜力,同时也强调了标准化方案和长期安全性评估的必要性。
Safety and Efficacy of Stem Cell Therapy in Ischemic Stroke: A Comprehensive Systematic Review and Meta-Analysis.
Background: Although recent advancements in ischemic stroke management have reduced associated mortality rates, there remains a pressing need for more reliable, efficacious, and well-tolerated therapeutic approaches due to the narrow therapeutic window of current treatment approaches. The current meta-analysis sought to evaluate the safety and efficacy of stem cell-based therapeutic options for patients with ischemic stroke. Methods: PubMed, Web of Science, and Cochrane library databases were searched to retrieve randomized controlled trials (RCTs) evaluating the efficacy and safety of stem cell therapy (SCT) in ischemic stroke patients. Key outcomes included the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA), infarct size, and safety profile. The random effects model with the continuous method was used to calculate the pooled effect size in Review Manager 5.4.1, and subgroup analyses were performed based on demographics, stroke duration, and SCT delivery protocols. Results: A total of 18 RCTs involving 1026 patients were analyzed, with 538 in the treatment group and 488 in the control group. The mean change in NIHSS score was comparable between groups [MD = -0.80; 95% CI: -2.25, 0.65, p < 0.0001]. However, SCT showed better outcomes in mRS [MD = -0.56; 95% CI: -0.76, -0.35, p = 0.30] and BI scores [MD = 12.00; 95% CI: 4.00, 20.00, p = 0.007]. Additionally, the mean change in FMA score was significantly greater with SCT [MD = 18.16; 95% CI: 6.58, 29.75, p = 0.03]. The mean change in infarct volume also favored stem cell therapy [MD = 8.89; 95% CI: -5.34, 23.12, p = 0.08]. The safety profile was favorable, with adverse event rates comparable to or lower than controls. Conclusions: SCT offers a safe and effective approach to improving functional outcomes in stroke patients, particularly with early intervention. These findings highlight the potential of SCT in ischemic stroke rehabilitation while underscoring the need for standardized protocols and long-term safety evaluation.
期刊介绍:
Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals.
Unique features of this journal:
manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes.
There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.